**To the Editor:** The proposal by Stringer et al. to change the name of *Pneumocystis carinii* found in humans to *Pneumocystis jirovec* requires critical consideration ([@R1]). First, their rationale for the choice of Jírovec is not compelling. Principle III of the International Code of Botanical Nomenclature (ICBN) states: "the nomenclature of a taxonomic group is based upon priority of publication" ([@R2]). Jírovec's publication in 1952 was not the first to report *P. carinii* infection in human lungs. In 1942, two Dutch investigators, van der Meer and Brug, described *P. carinii* as the infecting organism in a 3-month-old infant with congenital heart disease and in 2 of 104 autopsy cases (a 4-month-old infant and a 21-year-old adult) ([@R3]). Their description, photomicrographs, and drawings of *P. carinii* are unequivocal. They also described the typical "honeycomb" patterns in alveoli. In 1951, Dr. Josef Vanek at Karls-Universität in Praha, Czechoslovakia, reported his study of lung sections from 16 children with interstitial pneumonia and demonstrated that the disease was caused by *P. carinii* ([@R4]). Vanek notes in his report, "In man the parasite was for the first time established as a cause of pneumonia in a child by G. Meer and S. L. Brug (1942)." In 1952, Jírovec reported *P. carinii* as the cause of interstitial plasmacellular pneumonia in neonates ([@R5]). A year later, in a coauthored publication, Vanek, Jírovec, and J. Lukes acknowledged and referenced the earlier reports of van der Meer and Brug and Vanek ([@R6]). If principle III is to be followed, as well as fairness to the investigators, both van der Meer and Brug and Vanek hold priority over Jírovec, assuming the designation of the species name should be based on the name of the first person to discover *P. carinii* in humans.

The nomenclature of *P. carinii* has actually been fraught with errors from the beginning. In the earliest publications, Carlos Chagas and Antonio Carini mistook the organism for stages in the life cycle of trypanosomes. Chagas placed it in a new genus, *Schizotrypanum* ([@R7],[@R8]). In 1912, Delanoë and Delanoë at the Pasteur Institute in Paris published the first description of the organism as a new entity unrelated to trypanosomes ([@R9]). They proposed the name *"Pneumocystis carinii"* as a tribute to Carini. The Delanoë paper has remained unchallenged as the original description of *P. carinii*. Both Chagas and Carini later acknowledged their errors and the validity of the Delanoës' conclusion. By current ICBN principles, *P. carinii* is acceptable nomenclature because the authors of the first publication proposed the name of Carini, rather than their own.

In addition, changing the name to *P. jiroveci* will create confusion in clinical medicine where the name *P. carinii* has served physicians and microbiologists well for over half a century. I was moved to write this letter because of a call from a knowledgeable oncologist asking for information on "the new strain of *P. carinii* that has just been reported from the Centers for Disease Control and Prevention," referring to the report by Stringer et al ([@R1]).

AIDS patients are well informed about *P. carinii* pneumonia and avidly monitor medical news about their disease. Without doubt, the name change will cause confusion and undue anxiety among the many thousands of HIV-infected patients who attend clinics. Health-care workers will have an added burden of explaining why the name was changed, but the organism and infection are unchanged. Also, versions of the pronunciation of *jiroveci* (yee row vet zee) by American patients, physicians, and health-care workers will be interesting to hear.

The tone of the article by Stringer et al. implies that the change of *P. carinii* to *P. jiroveci* is final, which is not the case. The nomenclature of fungi is governed by ICBN under the auspices of the International Botanical Congress and is not based solely on molecular genetics. Neither *P. carinii* nor *P. jiroveci* have been submitted for ICBN scrutiny. In another paper, Stringer et al. outline the mechanics for submission, but indicate that no application has been submitted for their proposal ([@R10]). In fact, *P. carinii* has not been acknowledged as a fungus by ICBN or any other authoritative taxonomic system. Only when nomenclature is registered in ICBN, can a name be referred to as "formally accepted." In the meantime, the workable terminology proposed earlier by Stringer et al. in 1994 ([@R11]) will suffice for clinical use.

In Response
===========

We appreciate Dr. Hughes' letter of concern regarding our article endorsing the name *Pneumocystis jiroveci* ([@R12]). When working with well-known disease agents and syndromes, these types of changes are more difficult to adopt because of the effect they have on daily communication, patient care, record keeping, and other important routines of health-care providers. However, in this case, new information and understanding dictate that a change be made.

For some time, scientists have known that humans are infected by a particular species of *Pneumocystis* and that this species does not infect other host species. In recognition of these facts, Frenkel named the human pathogen *Pneumocystis jiroveci,* using the procedure prescribed by the International Code of Botanical Nomenclature (ICBN) ([@R13]). Although Dr. Hughes raised a number of issues, none justifies rejecting the new, valid name.

Dr. Hughes suggested that the name *P. jiroveci* is incorrect on the basis of principal III of ICBN, which holds that "the nomenclature of a taxonomic group is based upon priority of publication." He indicated that Jírovec was not the first investigator to report *Pneumocystis* in humans. Although this situation may be the case, principal III has not been violated because "priority of publication" refers to the time when a name is validly published, not to the time when an organism is first described. The name *P. jiroveci* was validly published in 1999, and this name therefore has priority. To be valid, all of the following steps must be completed: a name must be published in a scientific journal, the name must be a binary Latin name, the organism must be described in Latin, the rank of the organism must be indicated, and the new species must be called by the term "typus or holotypus,"and the specimen or microscope slides must be placed in a public holding (details are available from: URL: <http://www.bgbm.fu-berlin.de/iapt/nomenclature/code/SaintLouis/0000St.Luistitle.htm>). Dr. Frenkel was the first to fulfill these requirements in his 1999 publication ([@R13]).

The 1912 publication by Delanoë and Delanoë does not have priority in naming *Pneumocystis* from humans because the organism studied by the Delanoës was from the rat. The rat-derived *Pneumocystis* organism continues to be known as *P. carinii*, in keeping with principal III. As an additional historical note, Dr. Frenkel was the first investigator to understand the clear differences between human and rat-derived *Pneumocystis*, which were described in a landmark publication in 1976 ([@R14]). He proposed a change in nomenclature in which the name *Pneumocystis jiroveci* n. sp. applied to the human organisms and *Pneumocystis carinii* was retained for the rat organism. However, Frenkel did not attempt to follow ICBN procedures because at the time *Pneumocystis* was thought to be a protozoan. Nevertheless, this early paper established the idea of naming human *Pneumocystis*, *P. jiroveci*.

Dr. Hughes stated a concern over the possibility that the name change may cause "confusion and undue anxiety among the many thousands of HIV-infected patients who attend clinics." Such concern is understandable. However, patients will have guidance in understanding the significance of the name change. Health-care providers will allay any fears that might be elicited by the application of the new name. The level of anxiety experienced by persons at risk of acquiring *Pneumocystis carinii* pneumonia (PCP) is more likely to decline than to increase. People may be relieved to learn that they are not going to catch PCP from a pet, for example.

Dr. Hughes suggested that the name *P. jiroveci* is unofficial because it has not yet been sanctioned by a body of experts that scrutinizes proposed name changes and has the power to either accept or reject them. This situation is not the case. The process by which new names are validated does not directly involve a body of experts. The International Botanical Congress does not evaluate names. Instead, the congress has established ICBN, which sets forth the procedures authors must follow to publish a valid new name. The scientific basis for the new name is included in the publication. In the case *of P. jiroveci*, abundant evidence shows that *P. carinii* and *P. jíroveci* are different species. This evidence, which also indicates that the genus *Pneumocystis* contains many additional species, has been reviewed extensively ([@R15],[@R16]). Dr. Hughes gave the impression that that this evidence is exclusively molecular genetic data. In fact, the molecular genetic evidence is mirrored by clear biologic differences, the most dramatic being host species specificity.

As our knowledge of the biology and genetics of disease-causing microorganisms grows, openness to changes in the taxonomy and classification is needed. Given the impact such changes can have outside of the realm of basic science, the decision to accept the proposed changes in the nomenclature used for *Pneumocystis* has not been made frivolously. This decision is the result of a long and deliberate process that began almost 10 years ago, when data demonstrating that different mammalian hosts harbor different *Pneumocystis* species first began to appear. In 1994 and 2001, nomenclature issues were discussed at international meetings of the *Pneumocystis* community, with both physicians and research investigators present. In 1994, the data supporting new species were relatively limited. Consequently, a provisional tripartite nomenclature was adopted in lieu of recognizing new species ([@R17]). By 2001, however, the existence of multiple species and the necessity of assigning new species names were accepted by consensus. Because Frenkel had already published the name *P. jiroveci*, the suitability and validity of this name were also discussed. The new name was approved by consensus ([@R15]). We recognize that the results of these meetings do not necessarily reflect all opinions on the matter of *Pneumocystis* nomenclature, but we know of no better way to assess the majority opinion.

In endorsing the name *Pneumocystis jiroveci*, we hope to foster scientific understanding and communication. The tripartite name formerly used to denote the distinctness of this organism is not only cumbersome, it is inadequate because its meaning is not apparent and must be defined every time it is used. The arcane nature of the tripartite name tended to deprive the broad audience of persons interested in PCP of vital information, namely, a unique species of *Pneumocyctis* infects humans. By contrast*,* the new species name clearly states the uniqueness of *P. jiroveci*; a distinction is needed when assessing the significance of findings obtained by studies on other members of the genus. Recognition of this uniqueness will undoubtedly stimulate more research on this species. Communication will best be served by uniformity in nomenclature.

Frenkel has assigned a valid name to the *Pneumocystis* species found in humans. Ignoring this name on the grounds of inconvenience is not only unjustified, it is impractical. If names published in accordance with ICBN are not accepted, the field will have no recognized mechanism for conferring names, fostering the use of idiosyncratic, inadequate, and misleading names. Communication and progress will suffer as a result. Furthermore, if we choose to ignore critical changes in taxonomy for subjective reasons, when these changes are mandated by new and indisputable information, then taxonomy itself becomes meaningless and as a consequence, practitioners of public health, clinical medicine, and biomedical research might as well call any disease agent by whatever name they choose.
